Last reviewed · How we verify

Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Phase 2 active Small molecule

Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine is a Small molecule drug developed by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano. It is currently in Phase 2 development.

At a glance

Generic namePalonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine
SponsorFondazione IRCCS Istituto Nazionale dei Tumori, Milano
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine

What is Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine?

Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine is a Small molecule drug developed by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.

Who makes Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine?

Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine is developed by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (see full Fondazione IRCCS Istituto Nazionale dei Tumori, Milano pipeline at /company/fondazione-irccs-istituto-nazionale-dei-tumori-milano).

What development phase is Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine in?

Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine is in Phase 2.

Related